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Tl. While the majority of nuclear medicine procedures use Auger electron emitters in planar imaging and single photon emission computed tomography (SPECT), positron emitters are also used extensively. Their principal uses in diagnostic nuclear medicine are 18 F for diagnosis of cancer with positron emission tomography (PET) and 133 Xe for lung perfusion imaging. The most common examples of therapeutic beta emitters are 131 I for treatment of Grave's disease and cancer, 90 Y for cancer, 89 Sr for palliation of bone pain, and occasionally 32 P for polycythemia vera. Finally, alpha particle emitters such as 225 Ac and 223 Ra are currently under experimental evaluation for therapy of a variety of conditions.
Biological damage caused by Auger processes that arise from radioactive decay has been a topic of considerable interest in radiobiology and diagnostic radiology. The keen interest in these radionuclides began when it was observed by Feinendegen (1968) , and later by others (Ertl et al. 1970; Hofer and Hughes 1971; Bradley et al. 1975; Feinendegen 1975) , that Auger electron emitters can be highly radiotoxic when they decay within the DNA. Under these conditions, Auger emitters can be as radiotoxic as 210 Po, which emits 5.3 MeV alpha particles Rao et al. 1990 ). In contrast, cytoplasmic localization and even some intranuclear localizations elicit radiotoxicities analogous to emitters of low linear energy transfer (LET) radiations. Several comprehensive reviews have been published on the biological effects of Auger electron emitters (Sastry and Rao 1984; Sastry 1992; Kassis 2004; Buchegger et al. 2006; Nikjoo et al. 2006; Howell 2008) . These are excellent resources for extensive backgrounds and analyses of the field.
When an atom undergoing EC or IC is ionized by removing an electron from an inner atomic shell, the residual atom is in an excited state. Relaxation back to the ground state occurs rapidly via radiative and nonradiative processes. Radiative and non-radiative processes involve the emission of characteristic x-rays and Auger electrons, respectively. These are competitive processes, with radiative processes being more probable for K-shell vacancies and non-radiative processes being more probable for vacancies in the L-shell and above. Thus, creation of an initial inner atomic shell vacancy leads to a series of atomic transitions involving the emission of characteristic x-rays and Auger electrons. This phenomenon, historically referred to as the Auger effect, leads to the emission of a shower of characteristic x-rays and Auger electrons (Fig. 2) . Most of these Auger electrons have very low energies (ϳ20 eV to 500 eV) with ranges ϳ1-10 nm in tissue. As a consequence, biomolecules in the vicinity of the decay are subject to the direct effects of electron irradiation and indirect effects caused by radical species that arise from the radiolysis of water (Wright et al. 1990 ). In addition, the molecule containing the excited atom is subject to damage caused by charge neutralization (Pomplun and Sutmann 2004) .
Many advances have been made in terms of understanding of the biological effects of Auger processes and their application in medicine. A puzzling dichotomy of opinions exists with respect to the significance of their biological effects. Paradoxically, they are often largely ignored by international organizations that assess radiation risks from low doses of ionizing radiation, while at the same time their extreme radiotoxicity is touted as the perfect precision strike against disease (Feinendegen 1975) . Thus, there is much to learn about these curious electrons, which have seemingly impotent energies when considered alone but, when emitted as a shower of low-energy electrons, deposit a highly localized energy density (HILED) of Ͼ10 MGy in a diameter of about 1 nm around the decay site (Sastry and Rao 1984; Sastry 1992) .
The radiotoxicity of ␤ particles emitted by nuclear medicine radionuclides is generally considered low-LET. The common therapeutic ␤-emitters 131 I, 133 Xe, 90 Sr, 90 Y, and 32 P emit particles with mean energies of about 0.2, 0.1, 0.2, 0.9, and 0.7 MeV, respectively. While the effects of these emitters are usually commensurate with low-LET x-rays and ␥-rays, 131 I has sometimes demonstrated itself to be several times more lethal when incorporated into the DNA (Neti and Howell 2004 ). Whaley and Little have also shown that localized energy deposition by DNA-incorporated 131 I and 125 I contributes to cytotoxic and mutagenic effects in cells (Whaley and Little 1990) . However, the ␤-emitting radiopharmaceuticals used in diagnostic and therapeutic nuclear medicine do not localize in this fashion.
Long-lived ␣-emitters were used long ago in diagnostic medicine, sometimes with unfortunate results. For example, thorium dioxide (ThO 2 ), also known as Thorotrast, was used as a contrast agent in x-ray diagnostics from 1930 to 1950. The very long biological clearance time of this agent, coupled with the ␣-particles emitted by 232 Th, resulted in high organ equivalent doses and corresponding increases in cancer incidence among this patient population. These and other untoward events slowed the development of ␣-emitters for therapeutic nuclear medicine. However, over the last two decades, there has been a steady increase in the use of ␣-emitters with relatively short physical half-lives for targeted radioimmunotherapy. These agents are being designed to deliver radiation doses as small as possible to healthy organs, while selectively targeting tumor tissue with high doses.
The maximum equivalent dose to any given organ from diagnostic radiopharmaceuticals is restricted to Ͻ50 mGy, and absorbed doses that approach this magnitude are the exception. While it is generally very difficult to observe statistically-significant radiation responses that are caused by acute or chronic irradiation at equivalent doses below 50 mGy, it is possible to measure some biologic responses in highly radiosensitive organs such as the testes and bone marrow. For example, murine spermhead abnormalities can be measured at doses below 50 mGy (Rao et al. 1991) . Depending on the subcellular distribution of the radiochemical, the relative biological effectiveness (compared to acute external x-rays) for induction of spermhead abnormalities ranges from 2-60 (Rao et al. 1991) . While these RBE values are quite high, it should be noted that no links between induction of spermhead abnormalities and risk to parent or offspring have been demonstrated, although it has been shown that intravenous injection of the Auger emitter 55 Fe can increase the probability of chemically-induced cancer in the offspring of irradiated males (Hoyes et al. 2001) . Marked induction of cell transformations and hprt mutations at very low doses, with corresponding high RBE values, have also been demonstrated for DNA-incorporated 125 I, a prolific Auger electron emitter (LeMotte et al. 1982; Nagasawa et al. 1992) . With this in mind, it is interesting to reflect on Moore and Sastry's hypothesis that the Auger electrons emitted by 40 K may have played a significant role as a mutagen during primordial evolution (Moore and Sastry 1982) . These and related findings have been considered by some advisory bodies in making recommendations regarding risk estimates for internal radionuclides (Humm et al. 1994; Goodhead et al. 2004; ICRP 2007) . It is generally concluded that there is the possibility of increased risk from Auger emitters depending on the subcellular location and nonuniform distribution between cells within tissues, though the radiation weighting factor for Auger electrons is assigned a value of 1, as it is for ␤-emitters and other low-LET radiations. This implies that their risk for inducing stochastic effects is comparable to x-and ␥-rays. However, the ICRP recognizes that Auger electron-emitting radiopharmaceuticals represent a special case that requires individual attention when they incorporate into DNA (Goodhead et al. 2004; ICRP 2007; Harrison and Day 2008) .
In addition to the highly localized energy density (HILED) that is deposited by Auger electron emitters, a very important aspect of risk assessment for these and other internal radionuclides is the observation of highly nonuniform distribution of radiopharmaceuticals even among cell populations wherein all cells are exposed to the same extracellular radiopharmaceutical concentration. It would appear that log normal distributions of radioactivity are ubiquitous, and the standard deviation of this distribution can have a profound impact on the toxicity of a given radiopharmaceutical (Neti and Howell 2006) . This should be addressed on an individual basis for each radiopharmaceutical (Goodhead et al. 2004; ICRP 2007; Harrison and Day 2008) .
Recently, a comprehensive analysis of the cancer risk from internally-deposited radionuclides was published (Raabe 2010) . This report addressed chronic irradiation by ␣-and ␤-emitters localized in lung and in bone. Raabe showed that cancer risk associated with protracted irradiation from internally-deposited radionuclides is a non-linear function of lifetime average dose rate to the affected tissues in beagle dogs. Based on these observations, it was stated that, "Cumulative radiation dose is neither an accurate nor an appropriate measure of cancer risk for protracted ionizing radiation exposure" (Raabe 2010) . Observations of other biological endpoints such as killing of murine granulocyte macrophage-colony forming cells (GM-CFC) in bone marrow and spermatogonial cells in testes also indicate that cumulative radiation dose is not an appropriate variable to predict response Goddu et al. 2000) . While a threshold was not observed for murine cell killing in the bone marrow and testes Goddu et al. 2000) , cancer associated with a protracted low dose-rate exposure of beagle dogs to low-and high-LET ionizing radiation involves a lifespan virtual threshold when the lifetime average dose rate is low (Raabe 2010) . The minimum thresholds for induction of lung cancer in young adults were about 0.5 and 5 Gy for ␣-and ␤-emitters, respectively, in the lungs. The corresponding thresholds for induction of bone sarcoma were 1 and 20 Gy for ␣-and ␤-emitters, respectively, in bone. These absorbed dose thresholds are far beyond the doses delivered by nuclear medicine procedures, although it must be noted that because of the relatively short physical half-lives of radionuclides used in nuclear medicine, exposures in nuclear medicine are protracted over hours, days, or weeks, not over a lifetime.
Scientific evidence indicates that the risks associated with exposure to the low dose and low-dose rates encountered in diagnostic nuclear medicine are minimal. In contrast, there are enormous medical benefits afforded by the diagnostic capabilities of nuclear medicine in that they often eliminate the need for invasive procedures such as catheterization and interventional radiology and highly invasive exploratory surgery. While the inherent risks associated with therapeutic nuclear procedures are higher, the potential benefits are often lifesaving. Therefore, radiopharmaceuticals will continue to play an indispensable role in medicine, and the continued development of even more effective radiopharmaceuticals will play an essential role in the future of medicine.
